Seeking to boost the notoriously modest in vivo activity of CAR-T cells expressing a CD27-based CAR against acute myeloid leukemia cells expressing the CAR target antigen CD70 at mediocre levels, Leick et al. adopted a pharmacological approach predicated on the demethylating agent azacitidine to enhance the density of CD70 on AML cells [18] (Figure 1). Here, CD70 is linked to acute myeloid leukemia.